tradingkey.logo

Marker Therapeutics Inc

MRKR
View Detailed Chart

1.000USD

-0.260-20.63%
Close 08/26, 16:00ETQuotes delayed by 15 min
11.30MMarket Cap
LossP/E TTM

Marker Therapeutics Inc

1.000

-0.260-20.63%
Intraday
1m
30m
1h
D
W
M
D

Today

-20.63%

5 Days

-11.50%

1 Month

-35.90%

6 Months

-34.64%

Year to Date

-67.85%

1 Year

-72.97%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 3 analysts
BUY
Current Rating
8.167
Target Price
548.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Marker Therapeutics Inc
MRKR
3
CRISPR Therapeutics AG
CRSP
29
Ionis Pharmaceuticals Inc
IONS
27
Intellia Therapeutics Inc
NTLA
27
Exact Sciences Corp
EXAS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Strong sell
Sell(11)
Neutral(1)
Buy(0)
Indicators
Sell(5)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Sell
RSI(14)
33.246
Neutral
STOCH(KDJ)(9,3,3)
36.577
Sell
ATR(14)
0.110
High Vlolatility
CCI(14)
-134.531
Sell
Williams %R
94.118
Oversold
TRIX(12,20)
-0.987
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.184
Sell
MA10
1.206
Sell
MA20
1.239
Sell
MA50
1.436
Sell
MA100
1.343
Sell
MA200
1.919
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Ticker SymbolMRKR
CompanyMarker Therapeutics Inc
CEODr. Juan F. Vera, M.D.
Websitehttps://markertherapeutics.com/
KeyAI